Haematology: Acute Lymphoblastic Leukaemia

Haematology: Acute Lymphoblastic Leukaemia Miniseries (Part 1): Until now, the use of minimal residual disease (MRD) testing in patients with acute lymphoblastic leukaemia (ALL) outside of a clinical trial program has not been standardised. Testing has been dependent on factors such as patient age and transplant considerations, largely because testing has not been funded through the Medicare Benefits Schedule (MBS). Well, that’s all changed, and now all patients with ALL are eligible for a total of twelve MRD tests per disease episode.

So, how will this affect clinical decisions, what will it mean for the treatment landscape, and how do we decide at what intervals to do these tests? Listen to this two-part interview to learn more…

Haematology: Acute Lymphoblastic Leukaemia Miniseries (Part 2): Until now, the use of minimal residual disease (MRD) testing in patients with acute lymphoblastic leukaemia (ALL) outside of a clinical trial program has not been standardised. Testing has been dependent on factors such as patient age and transplant considerations, largely because testing has not been funded through the Medicare Benefits Schedule (MBS). Well, that’s all changed, and now all patients with ALL are eligible for a total of twelve MRD tests per disease episode.

So, how will this affect clinical decisions, what will it mean for the treatment landscape, and how do we decide at what intervals to do these tests? Listen to this two-part interview to learn more…